Literature DB >> 31924264

Goats naturally devoid of PrPC are resistant to scrapie.

Øyvind Salvesen1, Arild Espenes2, Malin R Reiten2,3, Tram T Vuong3, Giulia Malachin2, Linh Tran3, Olivier Andréoletti4, Ingrid Olsaker2, Sylvie L Benestad3, Michael A Tranulis2, Cecilie Ersdal5.   

Abstract

Prion diseases are progressive and fatal, neurodegenerative disorders described in humans and animals. According to the "protein-only" hypothesis, the normal host-encoded prion protein (PrPC) is converted into a pathological and infectious form (PrPSc) in these diseases. Transgenic knockout models have shown that PrPC is a prerequisite for the development of prion disease. In Norwegian dairy goats, a mutation (Ter) in the prion protein gene (PRNP) effectively blocks PrPC synthesis. We inoculated 12 goats (4 PRNP+/+, 4 PRNP+/Ter, and 4 PRNPTer/Ter) intracerebrally with goat scrapie prions. The mean incubation time until clinical signs of prion disease was 601 days post-inoculation (dpi) in PRNP+/+ goats and 773 dpi in PRNP+/Ter goats. PrPSc and vacuolation were similarly distributed in the central nervous system (CNS) of both groups and observed in all brain regions and segments of the spinal cord. Generally, accumulation of PrPSc was limited in peripheral organs, but all PRNP+/+ goats and 1 of 4 PRNP+/Ter goats were positive in head lymph nodes. The four PRNPTer/Ter goats remained healthy, without clinical signs of prion disease, and were euthanized 1260 dpi. As expected, no accumulation of PrPSc was observed in the CNS or peripheral tissues of this group, as assessed by immunohistochemistry, enzyme immunoassay, and real-time quaking-induced conversion. Our study shows for the first time that animals devoid of PrPC due to a natural mutation do not propagate prions and are resistant to scrapie. Clinical onset of disease is delayed in heterozygous goats expressing about 50% of PrPC levels.

Entities:  

Year:  2020        PMID: 31924264     DOI: 10.1186/s13567-019-0731-2

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  5 in total

Review 1.  The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts.

Authors:  Izabella Grimaldi; Felipe Saceanu Leser; José Marcos Janeiro; Bárbara Gomes da Rosa; Ana Clara Campanelli; Luciana Romão; Flavia Regina Souza Lima
Journal:  J Mol Med (Berl)       Date:  2022-09-03       Impact factor: 5.606

Review 2.  Chronic Wasting Disease (CWD) in Cervids and the Consequences of a Mutable Protein Conformation.

Authors:  Christopher J Silva
Journal:  ACS Omega       Date:  2022-04-04

3.  Prion protein in myelin maintenance: what does the goat say?

Authors:  Fredrik S Skedsmo; Arild Espenes; Michael A Tranulis
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

4.  Stability of BSE infectivity towards heat treatment even after proteolytic removal of prion protein.

Authors:  Jan P M Langeveld; Anne Balkema-Buschmann; Dieter Becher; Achim Thomzig; Romolo Nonno; Olivier Andréoletti; Aart Davidse; Michele A Di Bari; Laura Pirisinu; Umberto Agrimi; Martin H Groschup; Michael Beekes; Jason Shih
Journal:  Vet Res       Date:  2021-04-16       Impact factor: 3.683

5.  Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints.

Authors:  Eric Vallabh Minikel; Hien T Zhao; Jason Le; Jill O'Moore; Rose Pitstick; Samantha Graffam; George A Carlson; Michael P Kavanaugh; Jasna Kriz; Jae Beom Kim; Jiyan Ma; Holger Wille; Judd Aiken; Deborah McKenzie; Katsumi Doh-Ura; Matthew Beck; Rhonda O'Keefe; Jacquelyn Stathopoulos; Tyler Caron; Stuart L Schreiber; Jeffrey B Carroll; Holly B Kordasiewicz; Deborah E Cabin; Sonia M Vallabh
Journal:  Nucleic Acids Res       Date:  2020-11-04       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.